Company intelligence / Profile preview

Bionor Immuno AS

Ownership: Private
Employees: ~49
Development stage: Phase 2

Overview

Bionor Immuno has developed peptide-based therapeutic vaccines targeting HIV. Its lead candidate, Vacc-4x, demonstrated a reduction in viral load in a Phase II trial but did not meet primary endpoints. Combination strategies (“Shock & Kill”) with latency-reversing agents have shown promise in reducing the latent reservoir and controlling viral load. The company retains full rights to its main assets and continues preclinical development on additional candidates[2][8][10].

Therapeutic areas: Infectious Diseases
Modalities: Peptide-based vaccinesImmunotherapy
Industry: Biotech

Drug pipeline

1 asset

vacc-4x

Phase 2

Indications: HIV infection

Partnerships

Smerud Medical Research International (2017 clinical/regulatory partnership)[2]Celgene (romidepsin supply agreement for REDUC trial)[10]

Beyond the preview

Go deeper on Bionor Immuno AS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bionor Immuno AS.

Explore the full profile